If you have been reading about actin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-05. Numbers and descriptions here follow the published literature rather than marketing material.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
| Property | Value | Notes |
|---|---|---|
| Purity determination | Reversed-phase HPLC | UV detection commonly at 214 nm |
| Mass confirmation | Mass spectrometry | Compared against theoretical 888.5 Da |
| Powder storage | -20 C or below | Dry and protected from light |
| Reconstituted storage | Aliquoted and frozen | Avoid repeated freeze-thaw cycles |
| Reconstitution solvent | Sterile water or neutral buffer | Avoid extreme pH conditions |
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Once in the body, tPA has can cause the desired thrombolytic activity (see figure), or be inactivated and removed. In the bloodstream tPA has a half-life of 4 to 6 minutes. tPA can be bound by a plasminogen activator inhibitor, resulting in inactivation of its activity. The protein is then removed from the bloodstream by the liver. One of the specific receptors responsible for this processes is a protein known as the LDL Receptor-Related Protein (LRP1), which clears tPA which is bound to the Plasminogen Activator Inhibitor 1 (PAI-1). However, when present in a high enough concentration to counteract the effects of plasminogen activator inhibitor, tPA can bind plasminogen, cleaving off the bound plasmin from it. Plasmin, another type of protease, can either be bound by a plasmin inhibitor, or work to degrade fibrin clots, which is the main therapeutic pathway.
=== Advantages in animals === Balanced anesthesia has various advantages in veterinary cases: In certain circumstances it is considerably cheaper than the usual anesthesia. Secondly, it can reduce the death rate. Furthermore, it offers more stable operating conditions for veterinarians. It also increase animal safety and comfort. Balanced anesthesia can make patients calm by using drugs such as: medetomidine, diazepam or midazolam, and acepromazine. Keeping patients calm prior to surgery can avoid the unpredictable consequences of stress, such as tachypnea, hypertension and tachycardia which may be harmful to the anesthetized patients. In addition, anxiety and stress may cause the nociceptive pain. The balanced anesthesia therefore may therefore decrease those possible complications. Another advantage of using balanced anesthesia is that it can decrease the chance of adverse effects. All medicines may have adverse effect on patients; some serious adverse effects of anesthesia may be caused by inhalational anesthetic, although in general these medicines are highly safe and useful. Using the correct amount of balanced anesthetic agents, the adverse effects can be reduced to some extent. Balanced anesthesia can also minimize the pain patients suffer. Pain may delay wound healing, decrease appetite, and even result in death. Using the proper amount of analgesics can reduce the amount of inhalant anesthetics required and help patients reduce the pain.
== Side effects == Methyldopa is capable of inducing a number of adverse side effects, which range from mild to severe. Nevertheless, they are generally mild when the dose is less than 1 gram per day. Side effects may include:
== Epidemiology == The beta form of thalassemia is particularly prevalent among Mediterranean peoples, and this geographical association is responsible for its original name. Thalassemias resulted in 25,000 deaths in 2013, down from 36,000 deaths in 1990. In Europe, the highest concentrations of the disease are found in Greece, coastal regions in Turkey (particularly the Aegean Region such as İzmir, Balıkesir, Aydın, Muğla, and Mediterranean Region such as Antalya, Adana, Mersin), in southern Spain, in parts of Italy, particularly southern Italy. With the exception of the Balearics, the major Mediterranean Islands, such as Sicily, Sardinia, Malta, Corsica, Cyprus, and Crete are heavily affected. Other Mediterranean peoples, as well as those in the vicinity of the Mediterranean, also have high rates of thalassemia, including people from North Africa and West Asia. Far from the Mediterranean, South Asians are also affected, with the world's highest concentration of carriers (16–18% of the population) in the Maldives. The disease is also found in populations living in Africa, the Americas, and in Tharu people in the Terai region of Nepal and India. It is believed to account for much lower rates of malaria illnesses and deaths, accounting for the historic ability of Tharus to survive in areas with heavy malaria infestation while others could not. Thalassemias are particularly associated with people of Mediterranean origin, Arabs (especially Palestinians and people of Palestinian descent), and Asians.
== History == Vitacost began operations in 1994 as a catalog retailer of third-party vitamins and supplements under the name Nature's Wealth Company by its founder Wayne Gorsek. In 1999, the company launched Vitacost.com and introduced proprietary vitamins and supplements, which has since expanded to include food, beauty products and sports nutrition. The company completed construction of a manufacturing facility located in Lexington, North Carolina, in 2008. Effective September 1, 2012, Vitacost agreed to lease its manufacturing facilities to a third-party provider. On September 23, 2009, Vitacost went public. Vitacost shares traded on the NASDAQ were suspended on December 7, 2010, for financials not adding up. By the time the stock was reinstated by NASDAQ, the stock had lost most of its value with investors losing almost all of their investment. ("Gebben"). During 2010, the company expanded and upgraded its West Coast distribution facility located in Las Vegas, Nevada. The Company began a similar project for its east coast distribution center, located in Lexington, North Carolina in the spring of 2010, with the building construction completed in the first quarter of 2011. Gorsek was found guilty of securities fraud on January 28, 2003. The SEC Commission announced on this day that the Honorable Jeanne E. Scott, U.S. District Judge for the Central District of Illinois, has found two former brokers and stock promoters, Wayne F. Gorsek ("Gorsek") and Lyndell F.
Sources: en.wikipedia.org
With nearly every Syndicate member dead, the Colonists began to clear up any evidence of alien life and began to create human replacements called "Super Soldiers", on which the Colonists had been working covertly as an alternative slave race should the hybridization experiments be unsuccessful. To create Super Soldiers, the Colonists infect humans with a new strain of their virus, which slowly destroys and then rebuilds the body of the host. This process seems to involve a lengthy surgical procedure on abductees as opposed to simple infection (as with the black oil). As they have normal red blood and can replace individuals within powerful positions, they provide an ideal way for the Colonists to infiltrate humanity to ensure that the plans for colonization are uninterrupted. They are identifiable however by small spiny protrusions on the backs of their necks or by detailed analysis of a blood sample which shows their DNA exists as a complex with iron. Although they cannot shapeshift, Super Soldiers are practically unstoppable. They can survive being crushed by a garbage compactor, decapitation, and can rip through steel with their bare hands. The only known way to kill them takes advantage of their metallic biochemistry: their bodies are torn apart by the magnetic fields present near large deposits of magnetite ore. The Super Soldiers quietly fill the positions of power previously occupied by Syndicate members and rarely use human conspirators.
== Residual topology == Residual topology is a descriptive stereochemical term to classify a number of intertwined and interlocked molecules, which cannot be disentangled in an experiment without breaking of covalent bonds, while the strict rules of mathematical topology allow such a disentanglement. Examples of such molecules are rotaxanes, catenanes with covalently linked rings (so-called pretzelanes), and open knots (pseudoknots) which are abundant in proteins. The term "residual topology" was suggested on account of a striking similarity of these compounds to the well-established topologically nontrivial species, such as catenanes and knotanes (molecular knots). The idea of residual topological isomerism introduces a handy scheme of modifying the molecular graphs and generalizes former efforts of systemization of mechanically bound and bridged molecules.
In May 1945, following its defeat in World War II, Germany was occupied by the United States, Britain, France and the Soviet Union. All four occupation powers reorganised the territories by recreating the Länder (states), the constituting parts of federal Germany. The state of Prussia, whose provinces extended to all four zones and covered two thirds of Germany, was abolished in 1947. Special conditions were assigned to Berlin, which the four powers divided into four sectors. A united German state government existed in the city until it broke apart in 1948. After 1949, both West Berlin and East Berlin (officially only called Berlin) were in effect incorporated into the Federal Republic of Germany and the German Democratic Republic, respectively, despite not legally being part of these countries.
Thymopentin is a thymic polypeptide derivative which interacts with T cells and acts as an immunostimulant. As such, it was used in several clinical studies in the early years of the AIDS pandemic (from 1983 to 1985). Thymopentin helped to improve immunological condition in some patients for a brief time under specific treatments. It has also been investigated more recently for applications in the treatment of rheumatoid arthritis, and lung cancer.
== Legality and Regulation == The Early Warning System (EWS), operated by the European Monitoring Centre for Drugs and Drug addiction (EMCDDA), overseas illicit substances that appear in the market. Established in 1997, It formed part of the framework that allows the European Union to rapidly detect NPS that pose a risk to the public's health. Due to the tightening of legislation, most NPS are now illegal in the UK and Germany. Upon the emergence of NPS, this agency responds in the following manner:
Sources: en.wikipedia.org
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.
Mass spectrometry is the usual confirmatory method because it measures the intact mass. Reversed-phase chromatography is used alongside it to estimate purity.
Not directly. Reported percentages depend on the chromatographic method, detection wavelength, and integration criteria, so the underlying method details matter.
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.